Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

Advanced Chart

Key Stats

Today's Range
$0.03
$0.05
50-Day Range
$0.02
$0.08
52-Week Range
$0.00
$14.75
Volume
23,886 shs
Average Volume
120,908 shs
Market Capitalization
$109.80 thousand
P/E Ratio
0.01
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
See More Headlines

TCON Stock Analysis - Frequently Asked Questions

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter.

TRACON Pharmaceuticals's stock reverse split before market open on Wednesday, April 10th 2024.The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

Last Earnings
5/14/2024
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCON
CIK
1394319
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$3.73
Trailing P/E Ratio
0.01
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.59 million
Net Margins
N/A
Pretax Margin
145.93%
Return on Equity
-237.65%
Return on Assets
57.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.66
Quick Ratio
0.66

Sales & Book Value

Annual Sales
$12.05 million
Price / Sales
0.01
Cash Flow
$1.61 per share
Price / Cash Flow
0.02
Book Value
($0.37) per share
Price / Book
-0.09

Miscellaneous

Outstanding Shares
3,410,000
Free Float
3,228,000
Market Cap
$109.80 thousand
Optionable
No Data
Beta
1.37

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:TCON) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners